Original Article

The Effectiveness of Topiramate in the Treatment of Amphetamine and Methamphetamine Use Disorder: A Randomized Controlled Trial

Abstract

Objective: Limited studies have yet evaluated the effectiveness of topiramate in the treatment of amphetamine and methamphetamine addiction. Therefore, the aim of this study was to investigate the effectiveness of topiramate in the treatment of patients with this disorder.
Materials and methods: In this randomized, double-blind, placebo-controlled clinical trial, 52 patients with amphetamine and methamphetamine use disorder, within the age range of 16-60 years, were randomly divided into an intervention group (n = 26) and a placebo group (n = 26). The intervention group was treated with topiramate tablets with a starting dose of 50 mg, which was gradually increased to the target dose of 200 mg. The control group was treated with placebo. The duration of drug intervention in this clinical trial was 12 weeks, and all participants were evaluated before the intervention and 2, 4, 6, 8, 10, and 12 weeks after beginning the intervention. The Beck Depression Inventory, drug use temptation questionnaire, urine test, and side effects questionnaire were used as outcome measures to assess the patients. The data were analyzed using chi-square, independent t-test, and analysis of variance with repeated measurements.
Results: There was no significant difference between the intervention and placebo groups in depression at the beginning of the treatment and at the 4th, 8th, and 12th weeks after the intervention (P > 0.05). The urine test also showed no significant difference between the two groups at any of the evaluation stages (P > 0.05). Although there was no significant difference between the two groups in the drug use temptation results at the beginning and the 2nd, 4th and 6th weeks (P > 0.05), the level of drug temptation in the intervention group was significantly lower than the placebo group in the 8th, 10th, and 12th weeks (P < 0.05).
Conclusions: Topiramate can be effective in reducing the desire to use amphetamine and methamphetamine. However, further studies are needed to confirm these results.

1. Tarabar AF, Nelson LS. The resurgence and abuse of heroin by children in the United States. Curr Opin Pediatr. 2003;15(2):210-5.
2. Guha M. Diagnostic and statistical manual of mental disorders: DSM-5. Reference Reviews. 2014;28(3):36-7.
3. Sadri Damirchi E, Esmaili Ghazivalooi F. Effectiveness of Mindfulness-Based Cognitive Therapy in Craving, Dependency, and Cognitive Emotion Regulation in Drug-Dependent Women. Scientific Quarterly Research on Addiction. 2017;11(43):51-69.
4. González B, Jayanthi S, Gomez N, Torres OV, Sosa MH, Bernardi A, et al. Repeated methamphetamine and modafinil induce differential cognitive effects and specific histone acetylation and DNA methylation profiles in the mouse medial prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:1-11.
5. Kish SJ. Pharmacologic mechanisms of crystal meth. Cmaj. 2008;178(13):1679-82.
6. McPherson RA, Pincus MR. Henry's clinical diagnosis and management by laboratory methods E-book: Elsevier Health Sciences; 2021.
7. Haile CN, Kosten TR, Kosten TA. Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Am J Drug Alcohol Abuse. 2009;35(3):161-77.
8. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379(9810):55-70.
9. Cottencin O, Rolland B, Guardia D, Karila L. [Current data on methamphetamine]. Rev Prat. 2012;62(5):679-81.
10. Naidoo S, Smit D. Methamphetamine abuse: a review of the literature and case report in a young male. Sadj. 2011;66(3):124-7.
11. Khaleghi A, Mohammadi MR, Shahi K, Nasrabadi AM. Computational Neuroscience Approach to Psychiatry: A Review on Theory-driven Approaches. Clin Psychopharmacol Neurosci. 2022;20(1):26-36.
12. Pirnia B, Khosravani V, Maleki F, Kalbasi R, Pirnia K, Malekanmehr P, et al. The role of childhood maltreatment in cortisol in the hypothalamic-pituitary-adrenal (HPA) axis in methamphetamine-dependent individuals with and without depression comorbidity and suicide attempts. J Affect Disord. 2020;263:274-81.
13. Zhong N, Chen T, Zhu Y, Su H, Ruan X, Li X, et al. Smaller Feedback-Related Negativity (FRN) Reflects the Risky Decision-Making Deficits of Methamphetamine Dependent Individuals. Front Psychiatry. 2020;11:320.
14. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677-85.
15. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. Jama. 2007;298(14):1641-51.
16. Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 2004;75(3):233-40.
17. García Campayo J, Sobradiel N, Alda M, Mas A, Andrés E, Magallón R, et al. Effectiveness of topiramate for tobacco dependence in patients with depression; a randomised, controlled trial. BMC Fam Pract. 2008;9:28.
18. Leombruni P, Lavagnino L, Fassino S. Treatment of obese patients with binge eating disorder using topiramate: a review. Neuropsychiatr Dis Treat. 2009;5:385-92.
19. Tatsuta T, Kitanaka N, Kitanaka J, Morita Y, Takemura M. Lack of effect of anticonvulsant topiramate on methamphetamine-induced stereotypy and rewarding property in mice. Pharmacol Biochem Behav. 2007;87(1):48-55.
20. Akhondzadeh S, Hampa AD. Topiramate prevents ecstasy consumption: a case report. Fundam Clin Pharmacol. 2005;19(5):601-2.
21. Shakeri J, Ahmadi SM, Maleki F, Hesami MR, Parsa Moghadam A, Ahmadzade A, et al. Effectiveness of Group Narrative Therapy on Depression, Quality of Life, and Anxiety in People with Amphetamine Addiction: A Randomized Clinical Trial. Iran J Med Sci. 2020;45(2):91-9.
22. Ghassemzadeh H, Mojtabai R, Karamghadiri N, Ebrahimkhani N. Psychometric properties of a Persian-language version of the Beck Depression Inventory--Second edition: BDI-II-PERSIAN. Depress Anxiety. 2005;21(4):185-92.
23. Ziaee SS, Fadardi JS, Cox WM, Yazdi SA. Effects of attention control training on drug abusers' attentional bias and treatment outcome. J Consult Clin Psychol. 2016;84(10):861-73.
24. Rezaei F, Ghaderi E, Mardani R, Hamidi S, Hassanzadeh K. Topiramate for the management of methamphetamine dependence: a pilot randomized, double-blind, placebo-controlled trial. Fundam Clin Pharmacol. 2016;30(3):282-9.
25. Guglielmo R, Martinotti G, Quatrale M, Ioime L, Kadilli I, Di Nicola M, et al. Topiramate in Alcohol Use Disorders: Review and Update. CNS Drugs. 2015;29(5):383-95.
26. Silberstein SD. Topiramate in Migraine Prevention: A 2016 Perspective. Headache. 2017;57(1):165-78.
27. Fox CK, Marlatt KL, Rudser KD, Kelly AS. Topiramate for weight reduction in adolescents with severe obesity. Clin Pediatr (Phila). 2015;54(1):19-24.
28. Arbaizar B, Gómez-Acebo I, Llorca J. Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review. Gen Hosp Psychiatry. 2008;30(5):471-5.
29. Singh M, Keer D, Klimas J, Wood E, Werb D. Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized controlled trials. Addiction. 2016;111(8):1337-46.
30. Shank RP, Maryanoff BE. Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther. 2008;14(2):120-42.
31. Johnson BA. Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-of-concept study. Alcohol Clin Exp Res. 2004;28(8):1137-44.
32. Elkashef A, Kahn R, Yu E, Iturriaga E, Li SH, Anderson A, et al. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction. 2012;107(7):1297-306.
33. Johnson BA, Ait-Daoud N, Wang XQ, Penberthy JK, Javors MA, Seneviratne C, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry. 2013;70(12):1338-46.
34. Umbricht A, DeFulio A, Winstanley EL, Tompkins DA, Peirce J, Mintzer MZ, et al. Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. Drug Alcohol Depend. 2014;140:92-100.
35. Chan B, Freeman M, Kondo K, Ayers C, Montgomery J, Paynter R, et al. Pharmacotherapy for methamphetamine/amphetamine use disorder-a systematic review and meta-analysis. Addiction. 2019;114(12):2122-36.
36. Cohen J, Dervaux A, Laqueille X. [Topiramate in substance-related and addictive disorders]. Presse Med. 2014;43(9):892-901.
37. Minozzi S, Cinquini M, Amato L, Davoli M, Farrell MF, Pani PP, et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev. 2015;2015(4):Cd006754.
Files
IssueVol 18 No 4 (2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijps.v18i4.13624
Keywords
Amphetamine Drug Use Disorder Methamphetamine Randomized Controlled Trial Topiramate
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Moghaddam Sadegh A, Nazarinasab M, Behrouzian F, Rostami H, Mehrabi M. The Effectiveness of Topiramate in the Treatment of Amphetamine and Methamphetamine Use Disorder: A Randomized Controlled Trial. Iran J Psychiatry. 2023;18(4):371-379.